Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPRENDO
2024-519350-37-00Phase 2Completed
- Sponsor
- Institut Frauengesundheit
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and olaparib in breast cancer, sponsored by Institut Frauengesundheit. Primary endpoint: Overall response rate (confirmed CR or PR). Started Nov 2024; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-519350-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519350-37-00.